Newcastle Magnetic Resonance Centre

Projects

A phase 3 multicenter randomised double blind placebo controlled parallel group study to evaluate the efficacy and safety of Aducanumab (BIIB037) in subjects with early Alzheimer's Disease (ENGAGE)

Staff Profile: Dr Andrew Byrne